Key Alzheimer’s enzyme acts as tumor suppressor

Washington -- A recent research has found that gamma-secretase, an enzyme key to the progression of Alzheimer’s, acts as a tumor suppressor by shifting the pathway of epidermal growth factor receptor (EGFR), a potential treatment target for cancer.

Researchers at Burnham Institute for Medical Research (“Burnham”) have provided the first evidence that the Alzheimer’s enzyme acts as a tumor suppressor.
The findings reveal a limitation of targeting gamma-secretase for treatment of Alzheimer’s and potentially other diseases.

Amyloid precursor protein (APP) is found inside all cells. Although its function is unknown, it is linked to Alzheimer’s in the following way. APP can be cleaved by the enzymes beta-secretase and gamma-secretase, one after another. Upon gamma-secretase cleavage, amyloid-beta (AB) peptides are dispersed into the extra cellular matrix region and in due course combine into senile plaques, a trait of Alzheimer’s.

Existing inside cells, gamma-secretase is a compound of four proteins, including a family of proteins known as the presenilins (PS). Mutations in PS are found in approximately 5% of individuals suffering Alzheimer’s, resulting in early inception of the disease.

At the center of the activities governing AB production is gamma-secretase, the subject of thorough interest as a potential therapy target for Alzheimer’s. Mice deficient in PS/gamma-secretase activity tend to develop skin cancer. EGFR is known to be up regulated in a variety of tumors, including various skin cancers. Elevated EGFR levels in tumors are linked with poor clinical prognosis and tumor resistance to chemotherapy. EGFR is therefore the subject of intensive investigation by pharmaceutical companies as a potential treatment target for cancer.

The Xu laboratory started out to find out whether there might be a correlation between PS/gamma-secretase activity and EGFR. They examined mice with reduced PS gene dosage and found that there is a converse relationship between the level of EGFR and PS. They discovered that APP intracellular domain (AICD), another cleavage product of PS/gamma-secretase, negatively regulates transcription of the EGFR gene by binding the gene’s promoter region. They also demonstrated that deficient levels of APP correlate with increased levels of EGFR.

“Alzheimer’s disease and cancer are two of the most important medical research areas today”, said Huaxi Xu, associate professor and program director at Burnham. “We believe that our studies, which reveal a key role of Alzheimer’s PS/gamma-secretase-generated APP metabolite AICD in gene transcription and in EGFR-mediated tumorigenesis, should have a significant impact on both fields of research.” (ANI)